💨 Abstract

BioCryst Pharmaceuticals reported a Q2 net income of $5.1 million, a significant improvement over the same period last year. Earnings per share were 2 cents, with adjusted earnings at 15 cents per share, exceeding Wall Street's expectations. Revenue was $163.4 million, surpassing forecasts. The stock has risen 6% since the year's start and 13% over the past year.

Courtesy: WTOP Staff